news paper icon

Analyzed News

Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane

Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation. [Source]

Publication Date:


Category: companyNews

Topics: Merck, cancer, tepotinib, became, treatment, KGaA's prospective, watchdog's, priority, third drug, against, breakthrough, therapy designation, Administration's, that won, aggressive, subtype, disease


Related Articles